Masimo’s (MASI) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Masimo (NASDAQ:MASI) in a research note published on Wednesday,Benzinga reports.

A number of other research analysts have also weighed in on the stock. Raymond James boosted their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Stifel Nicolaus reissued a “buy” rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Wells Fargo & Company boosted their target price on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, Piper Sandler boosted their target price on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Masimo has an average rating of “Moderate Buy” and an average price target of $194.80.

Masimo Stock Up 12.3 %

MASI stock opened at $190.34 on Wednesday. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo has a 1 year low of $101.61 and a 1 year high of $191.10. The company has a fifty day simple moving average of $172.56 and a 200 day simple moving average of $152.84. The firm has a market cap of $10.19 billion, a PE ratio of 131.27 and a beta of 1.02.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. Sell-side analysts anticipate that Masimo will post 4.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Jones Financial Companies Lllp bought a new stake in Masimo in the fourth quarter valued at about $27,000. UMB Bank n.a. increased its stake in Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 123 shares during the period. Trust Co. of Vermont bought a new stake in Masimo in the fourth quarter valued at about $33,000. Blue Trust Inc. increased its stake in Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 71 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 64 shares during the period. Institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.